You make the tools while the scientists conduct science?
That’s exactly right,” says Dekkers. "If you walk into any lab, a lot of the instruments are bought from us.
Who’s your biggest competitor?
“Applied Biosystems (ABI), Agilent (A) and a variety of others,” says Dekkers.
When customers pick your products are you competing on price?
“It’s a technology buy. The price sensitivity is not significant,” Dekkers says. “They want the best possible tools to do (their jobs).”
Are your prices controlled by the government?
“Academia and government accounts for 20% of sales. Most comes from biotech pharma companies and contract research labs,” Dekkers says.
Since biotech is on fire – that’s good for your company?
"Yes. And diagnostic companies looking for new methodology also present a big growth area for TMO.” Dekkers adds: “We have quite a diversity in customers and product lines so we’re not a one trick pony.”
Dylan Ratigan asks the guys what they think of this stock?
Eric Bolling, Guy Adami and Pete Najarian all think TMO is a buy. Jeff Macke says one hiccup could be how the company will surprise investors in the future because they might be “too loved” now.
Got something to say? Send us an e-mail at email@example.com and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to firstname.lastname@example.org.
Trader disclosure: On May 22, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders: Macke Owns (SWY); Najarian Owns (MDT), (STI); Bollings Owns Coffee, Sugar, Gold, Silver, March Natural Gas Futures, Is Short April Natural Gas Futures